NeuroGenesis advancing innovative cell therapies to combat myelin-related neurodegenerative diseases, and Hadassah Medical Center announced highly positive results from a placebo-controlled Phase 2 clinical trial, headed by Prof. Dimitrios Karussis, together with Dr. Petrou Panayiota and Dr. Ibrahim Kassis from Hadassah Medical Center in Jerusalem, assessing the impact of NG-01 autologous proprietary subpopulation of mesenchymal stem cells (MSCs) on patients with progressive multiple sclerosis (MS). The results, recently published in Brain, a prestigious peer-reviewed journal published by Oxford University, and highlighted in the "Editor's Choice", show that: No serious, treatment-related safety issues were detected; Significantly fewer patients experienced treatment failure (disease progression) in the intrathecal (IT) and intravenous (IV) NG-01 treatment groups compared with those in the placebo group (6.7%, 9.7%, and 41.9%, respectively, P = 0.0003 and P = 0.0008); 58% of the patients treated intrathecally with NG-01 did not show Any Evidence of Disease Activity (NEDA) during the entire the treatment period (vs 9.7% in the placebo treated group) (P<0.0001); NG-01 treatment groups demonstrated a significant improvement in walking ability as measured by 25-foot walking time (P=0.0017); Intrathecal administration of NG-01 was more efficacious than intravenous in several key parameters of the disease: relapse rate (89% decrease in the relapse rate), functional MRI (improvement of motor networks), monthly changes of the MRI T2 lesion load and the 9-hole peg test, as compared to the control (placebo-treated) group.